Company press releases
Tid | Selskap | Tittel | Sektor | Kategori |
---|---|---|---|---|
22 Feb 2022 12:00 CET |
BERGENBIO | BerGenBio ASA: Share capital increase | 20103010 Biotechnology | Total number of voting rights and capital |
16 Feb 2022 17:10 CET |
BERGENBIO | BerGenBio ASA: Increase of share capital, exercise of share options | 20103010 Biotechnology | Kapital- og stemmerettsendringer |
16 Feb 2022 07:00 CET |
BERGENBIO | BERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021 | 20103010 Biotechnology | Inside information |
08 Feb 2022 07:00 CET |
BERGENBIO | BERGENBIO ASA: INVITATION TO FOURTH QUARTER 2021 RESULTS WEBCAST | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
03 Feb 2022 14:07 CET |
BERGENBIO | BerGenBio ASA: Share capital increase | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
27 Jan 2022 20:56 CET |
BERGENBIO | BerGenBio ASA: Increase of share capital, exercise of share options | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
27 Jan 2022 07:00 CET |
BERGENBIO | BerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients | 20103010 Biotechnology | Inside information |
10 Jan 2022 19:52 CET |
BERGENBIO | BerGenBio - Mandatory notification of trade by Primary Insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
07 Jan 2022 17:51 CET |
BERGENBIO | BerGenBio - Mandatory notification of trade by Primary Insiders | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
07 Jan 2022 09:04 CET |
BERGENBIO | BERGENBIO - Mandatory notification of trade by Primary Insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
06 Jan 2022 10:30 CET |
BERGENBIO | BERGENBIO APPOINTS ANDERS TULLGREN AS CHAIRMAN OF BOARD | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
06 Jan 2022 10:27 CET |
BERGENBIO | BerGenBio ASA: Extraordinary General Meeting held | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
06 Jan 2022 08:58 CET |
BERGENBIO | BerGenBio - Mandatory notification of trade by Primary Insiders | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
17 Dec 2021 13:43 CET |
BERGENBIO | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
16 Dec 2021 15:00 CET |
BERGENBIO | BerGenBio ASA: Notice of Extraordinary General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
16 Dec 2021 07:30 CET |
BERGENBIO | BerGenBio announces exclusive in-license of key intellectual property rights from UT Southwestern Medical Center | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
14 Dec 2021 07:43 CET |
BERGENBIO | BerGenBio to present at DNB Nordic Healthcare Conference 2021 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
13 Dec 2021 15:00 CET |
BERGENBIO | BERGENBIO PRESENTS UPDATED BEMCENTINIB AML DATA AT ASH 2021 MEETING | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |